Expanding Coverage NeurAxis has secured medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS) with two insurers covering approximately 700,000 lives, contributing to a total coverage of around 53 million nationally. This expansion signals growing acceptance and potential market penetration for neuromodulation therapies, providing opportunities to partner with payers and healthcare providers to increase product adoption.

Strong Revenue Growth Despite a relatively small revenue range of one to ten million dollars, NeurAxis demonstrated a 22 percent revenue growth in Q3 2025, indicating increasing market demand for neuromodulation solutions. This momentum may appeal to healthcare providers and clinics seeking innovative treatments for chronic and debilitating conditions, making it a prime target for new distribution and referral partnerships.

Positive Funding Moves The company successfully closed a $5 million registered direct offering, which could be leveraged to scale manufacturing, expand sales efforts, and accelerate product development. Engaging potential investors or strategic partners seeking growth opportunities in medical technology could further accelerate market penetration and sales reach.

Market Expansion Opportunities With recent medical policy approvals adding coverage for over 700,000 lives and plans to secure more payers, NeurAxis is positioned for rapid expansion in health insurance networks. Partnering with insurance companies and healthcare systems to promote reimbursement pathways can open new channels for device sales and clinical adoption.

Innovative Treatment Focus NeurAxis specializes in neuromodulation therapies for chronic conditions, addressing unmet needs in both adult and pediatric populations. Collaborations with hospitals, clinics, and healthcare providers focused on pain management, neurological disorders, and mental health could provide significant sales opportunities for their innovative solutions.